FDA Recall Database: Class II Recall: MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201 by Nipro Renal Soultions USA, Corporation

Key facts

What this classification means

A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.

What consumers should do

Facilities, clinicians, and consumers holding an affected unit or lot of MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201 should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Nipro Renal Soultions USA, Corporation. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Nipro Renal Soultions USA, Corporation should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Nipro Renal Soultions USA, Corporation directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.

Nipro Renal Soultions USA, Corporation’s FDA history

Argus HQ has recorded 4 total FDA actions tied to Nipro Renal Soultions USA, Corporation: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.

Frequently asked questions

Is MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and recalled?

Yes. FDA lists a Class II recall by Nipro Renal Soultions USA, Corporation for MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201, reported 20260916, with status "Ongoing." FDA recall number: Z-3133-2026.

What is the recall class for Nipro Renal Soultions USA, Corporation's recall?

FDA classified this recall as Class II. A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

Why was MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and recalled?

FDA's recall record states the reason as: Hemodialysis concentrates contain high endotoxin levels

Who should I contact about this recall?

Contact Nipro Renal Soultions USA, Corporation directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.

Related enforcement actions

• Recall: Nipro Renal Soultions USA, Corporation — Class II recall: Citric Complete Dry Citric Acid Concentrate REF: DCA+200-25 & DCA+203-25 →
• Recall: Nipro Renal Soultions USA, Corporation — Class II recall: Citric Complete Liquid Citric Acid Concentrate REF: LC+200-D,LC+201, LC+225(4… →
• Recall: Nipro Renal Soultions USA, Corporation — Class II recall: MedicaLyte Bicarbonate Powder REF: DB+201-2.1(45X) and DB+201-25 (35X, 36.83X… →